Certican
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The proliferation signal inhibitor everolimus (Certican), has demonstrated efficacy with full‐dose cyclosporine (CsA) (Neoral…
Everolimus (Certican) is an orally administered mammalian target of rapamycin inhibitor (proliferation signal inhibitor) derived…
The calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy in recent years, though their…
Background. Everolimus (Certican), a novel proliferation signal inhibitor, allows calcineurin inhibitor dose reduction in…
Everolimus (Certican) is a novel proliferation signal inhibitor with potent immunosuppressant effects that has been shown to…
Background. Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection…
Everolimus (Certican™) is being developed for prevention of acute and chronic rejection of solid organ transplants. A novel…
SDZ RAD (everolimus, Certican™) is a novel macrolide immunosuppressant that blocks growth factor-driven transduction signals in…